BAX

Across TCGA pan-cancer cohorts, BAX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BAX data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BAX mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BAX expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where BAX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.595	0.845	<.001	62	view →
LSCC	DFS	Median	III,IV	1.000	0.653	.009	9	view →
CCRCC	DFS	Quartile	All	0.625	0.898	.012	7	view →
PDAC	DFS	Tertile	IV	0.203	0.934	.024	6	view →
LUAD	DFS	Quartile	II,III,IV	0.678	0.264	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BAX–HNSC (OS)

Open the HNSC breakdown →